Kezar Life Sciences
KZR was delisted on the 8th of May, 2026.
43 hedge funds and large institutions have $28.2M invested in Kezar Life Sciences in 2024 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 16 increasing their positions, 13 reducing their positions, and 22 closing their positions.
833% more call options, than puts
Call options by funds: $84K | Put options by funds: $9K
52.19% more ownership
Funds ownership: 5.36% → 57.55% (+52%)
23% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 13
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
11% less capital invested
Capital invested by funds: $31.6M → $28.2M (-$3.42M)
27% less funds holding
Funds holding: 59 → 43 (-16)
73% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$2.65M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$655K |
| 3 |
SC
Shay Capital
New York
|
+$441K |
| 4 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$363K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$241K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
Acuitas Investments
Seattle,
Washington
|
-$949K |
| 2 |
AAA
Affinity Asset Advisors
New York
|
-$811K |
| 3 |
Renaissance Technologies
New York
|
-$313K |
| 4 |
Two Sigma Advisers
New York
|
-$299K |
| 5 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$292K |
KZR Hedge Fund Activity: Q4 2024 in Review
43 of the 7,597 institutional investors tracked by Wall St. Rank reported a position in Kezar Life Sciences (KZR) for Q4 2024, worth a combined $28.2M — down 11% from $31.6M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of KZR and 6 opened new positions — a net loss of 16 holders — while 13 trimmed existing stakes and 16 added.
The largest buyer was Tang Capital Management, adding an estimated $2.65M. The largest seller was Acuitas Investments, exiting entirely with an estimated $949K sold.
- 43 institutional investors held Kezar Life Sciences (KZR) as of Q4 2024, down from 59 in Q3 2024.
- Funds reported $28.2M of Kezar Life Sciences stock for Q4 2024, down 11% quarter-over-quarter.
- 6 funds opened new Kezar Life Sciences positions in Q4 2024 and 22 closed out, a net change of -16 holders.
- The largest Kezar Life Sciences buyer in Q4 2024 was Tang Capital Management, an estimated $2.65M added.
- The largest Kezar Life Sciences seller in Q4 2024 was Acuitas Investments, an estimated $949K sold.
Based on aggregated 13F filings for Q4 2024.